OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience

被引：9

作者：

Chiang, Chia-Chun ^{[2
]}

Starling, Amaal J. ^{[1
]}

机构：

[1] Mayo Clin Hosp, Dept Neurol, 5777 East Mayo Blvd, Phoenix, AZ 85054 USA

[2] Mayo Clin, Dept Neurol, Scottsdale, AZ USA

来源：

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS | 2017年 / 10卷 / 12期

关键词：

botulinum toxins; humans; migraine disorders; type A; PLACEBO-CONTROLLED PHASE; QUALITY-OF-LIFE; DOUBLE-BLIND; EPISODIC MIGRAINEURS; MEDICATION-OVERUSE; RESOURCE USE; HEADACHE; BURDEN; DISABILITY; MANAGEMENT;

D O I：

10.1177/1756285617731521

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Chronic migraine is a debilitating neurobiological disorder that affects approximately 1.4-2.2% of the population worldwide. Patients with chronic migraine have 15 or more headache days per month, with at least 8 days per month that meet the criteria for migraine. Injection of onabotulinumtoxinA, using a standardized injection protocol, was approved by the US Food and Drug Administration in 2010 for the treatment of chronic migraine. The approval was made based on results from two large, randomized, double-blind placebo-controlled trials: the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) trials. Since then, numerous studies have been performed investigating the short-term and long-term benefits, risks and complications of the use of onabotulinumtoxinA injections for the treatment of chronic migraine. The purpose of this narrative review is to describe the currently available clinical evidence for the use of onabotulinumtoxinA injections for treating patients with chronic migraine.

引用

页码：397 / 406

页数：10

共 38 条

[1] Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse [J].

Ahmed, Fayyaz ;

Zafar, Hassan W. ;

Buture, Alina ;

Khalil, Modar .

SPRINGERPLUS, 2015, 4

[2] OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial [J].

Aurora, S. K. ;

Dodick, D. W. ;

Turkel, C. C. ;

DeGryse, R. E. ;

Silberstein, S. D. ;

Lipton, R. B. ;

Diener, H. C. ;

Brin, M. F. .

CEPHALALGIA, 2010, 30 (07) :793-803

[3] OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program [J].

Aurora, Sheena K. ;

Winner, Paul ;

Freeman, Marshall C. ;

Spierings, Egilius L. ;

Heiring, Jessica O. ;

DeGryse, Ronald E. ;

VanDenburgh, Amanda M. ;

Nolan, Marissa E. ;

Turkel, Catherine C. .

HEADACHE, 2011, 51 (09) :1358-1373

[4] The International Classification of Headache Disorders, 3rd edition (beta version) [J].

Bes, Andre ;

Kunkel, Robert ;

Lance, James W. ;

Nappi, Giuseppe ;

Pfaffenrath, Volker ;

Rose, Frank Clifford ;

Schoenberg, Bruce S. ;

Soyka, Dieter ;

Tfelt-Hansen, Peer ;

Welch, K. Michael A. ;

Wilkinson, Marica ;

Olesen, Jes ;

Bousser, Marie-Germaine ;

Diener, Hans-Christoph ;

Dodick, David ;

First, Michael ;

Goadsby, Peter J. ;

Goebel, Hartmut ;

Lainez, Miguel J. A. ;

Lance, James W. ;

Lipton, Richard B. ;

Nappi, Giuseppe ;

Sakai, Fumihiko ;

Schoenen, Jean ;

Silberstein, Stephen D. ;

Steiner, Timothy J. ;

Olesen, Jes ;

Bendtsen, Lars ;

Dodick, David ;

Ducros, Anne ;

Evers, Stefan ;

First, Michael ;

Goadsby, Peter J. ;

Hershey, Andrew ;

Katsarava, Zaza ;

Levin, Morris ;

Pascual, Julio ;

Russell, Michael B. ;

Schwedt, Todd ;

Steiner, Timothy J. ;

Tassorelli, Cristina ;

Terwindt, Gisela M. ;

Vincent, Maurice ;

Wang, Shuu-Jiun ;

Olesen, J. ;

Evers, S. ;

Charles, A. ;

Hershey, A. ;

Lipton, R. ;

First, M. .

CEPHALALGIA, 2013, 33 (09) :629-808

[5] Chronic migraine in the population - Burden, diagnosis, and satisfaction with treatment [J].

Bigal, Marcelo E. ;

Serrano, Daniel ;

Reed, Michael ;

Lipton, Richard B. .

NEUROLOGY, 2008, 71 (08) :559-566

[6] Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS) [J].

Blumenfeld, A. M. ;

Varon, S. F. ;

Wilcox, T. K. ;

Buse, D. C. ;

Kawata, A. K. ;

Manack, A. ;

Goadsby, P. J. ;

Lipton, R. B. .

CEPHALALGIA, 2011, 31 (03) :301-315

[7] Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine [J].

Blumenfeld, Andrew M. ;

Aurora, Sheena K. ;

Laranjo, Karen ;

Papapetropoulos, Spyros .

BMC NEUROLOGY, 2015, 15

[8] Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine [J].

Bratbak, Daniel Fossum ;

Nordgard, Stale ;

Stovner, Lars Jacob ;

Linde, Mattias ;

Dodick, David W. ;

Aschehoug, Irina ;

Folvik, Mari ;

Tronvik, Erling .

CEPHALALGIA, 2017, 37 (04) :356-364

[9] Treatment of medication-overuse headache: A systematic review [J].

Chiang, Chia-Chun ;

Schwedt, Todd J. ;

Wang, Shuu-Jiun ;

Dodick, David W. .

CEPHALALGIA, 2016, 36 (04) :371-386

[10]

Diener HC, 2010, CEPHALALGIA, V30, P804, DOI 10.1177/0333102410364677

← 1 2 3 4 →